Showing 2131-2140 of 5554 results for "".
- Analysis: HS-Related Genetic Markers Predict Cardiometabolic Outcomeshttps://practicaldermatology.com/news/study-finds-hs-related-genetic-markers-predict-cardiometabolic-outcomes/2468406/A new cohort study suggests individuals with a high polygenic risk score (PRS) for hidradenitis suppurativa (HS) have an increased risk of developing coronary artery disease (CAD) and diabetes. Study researchers used data from 391,481 participants of European ancestry in the UK Biobank, e
- Hair Follicle-Derived KCs From AD Patients Could Help Study Inflammationhttps://practicaldermatology.com/news/hair-follicle-derived-kcs-ad-patients-could-help-study-inflammation/2468385/A new JID Innovations study suggests that hair follicle-derived keratinocytes (KCs) from patients with atopic dermatitits (AD) represent a useful model system to study AD-related inflammation in a personalized in vitro model. Researchers at Germany’s University Hospital Schleswig-Holstein
- Analysis: Higher Infection and Acne Risks with JAK Inhibitors in ADhttps://practicaldermatology.com/news/analysis-higher-infection-and-acne-risks-jak-inhibitors-ad/2468381/Researchers for a new analysis have provided a data and analytics framework for the evaluation of the safety of immune-modulating drugs (IMDs) in treating atopic dermatitis (AD). The study authors designed the system to generate timely, high-quality evidence using sequential propensity sco
- Long-Term Mortality in Epidermal Necrolysis Influenced by In-Hospital Complicationshttps://practicaldermatology.com/news/long-term-mortality-epidermal-necrolysis-influenced-hospital-complications/2468372/Epidermal necrolysis (EN) is associated with high in-hospital and post-discharge mortality rates, with comorbidities playing a significant role in outcomes. Researchers for the recent cohort study used French Health System data to characterize mortality and sequelae associated with EN, whi
- ISHRS to Host 32nd World Congress in Denver This Monthhttps://practicaldermatology.com/news/ishrs-host-32nd-world-congress-denver-month/2468370/From refinements in hair restoration surgical techniques to understanding the psychological and physiological aspects of hair loss, the latest research and concepts in hair growth and restoration will be presented by some of the world’s most renowned hair restoration experts when they convene in
- LITE: Home-Based UV-B Phototherapy Matches Office-Based Treatment in Psoriasishttps://practicaldermatology.com/news/lite-home-based-uv-b-phototherapy-matches-office-based-treatment-psoriasis/2468330/Results from a new study suggest home-based narrowband UV-B phototherapy for psoriasis is noninferior to office-based treatment in achieving clear skin and improving patient quality of life. The researchers conducted the analysis across 42 dermatology practices in the United States and inc
- DELTA FORCE: Delgocitinib Cream Superior for Chronic Hand Eczema Treatmenthttps://practicaldermatology.com/news/delta-force-delgocitinib-cream-superior-chronic-hand-eczema-treatment/2468306/New data from the DELTA FORCE trial presented at the 33rd European Academy of Dermatology and Venereology (EADV) Congress suggests that delgocitinib cream showed superior efficacy and safety compared to oral alitretinoin for the treatment of chronic hand eczema (CHE). “The completion of th
- SEEN Hair Care Closes $9 Million in Series A Fundinghttps://practicaldermatology.com/news/seen-hair-care-closes-9-million-series-funding/2468305/SEEN, the award-winning haircare brand developed by dermatologist Iris Rubin, MD, has closed a $9 million Series A funding. The company said in a press release that this investment will “accelerate SEEN's growth as the premier science-backed, clinically-proven beauty brand, which sits at the inte
- Anti-C5a Antibody Vilobelimab for HS to Be Presented at EADVhttps://practicaldermatology.com/news/anti-c5a-antibody-vilobelimab-hs-be-presented-eadv/2468302/InflaRx N.V. announced the e-poster presentation of a post hoc analysis of the SHINE Phase 2b study of its first-in-class anti-C5a antibody, vilobelimab, in hidradenitis suppurativa (HS) at the 2024 European Academy of Dermatology and Venereology (EADV) Congress being held in Amsterdam, Netherlan
- IGSRT Shows High Recurrence-Free Rates in Non-Melanoma Skin Cancerhttps://practicaldermatology.com/news/igsrt-shows-high-recurrence-free-rates-non-melanoma-skin-cancer/2468185/Nonmelanoma skin cancer (NMSC) treated with Image-Guided Superficial Radiation Therapy (IGSRT) showed consistently high freedom from recurrence rates, regardless of patient age or sex, according to a new analysis. The large retrospective cohort study, published in Geriatrics and c